Search

everythinglearnresearchcommunity

for

Search:↓

The document concludes that a systematic approach is crucial to identify causes of androgen excess in women beyond the most common cause, Polycystic ovary syndrome (PCOS).

Early diagnosis and personalized treatment of PCOS improve quality of life and prevent complications.

Chemotherapy and bone marrow transplant can cause permanent hair loss.

Lifestyle changes improve metabolism and fertility in overweight PCOS patients; anti-obesity drugs show potential but need more research.

Insulin resistance in women with PCOS can lead to serious health issues, but lifestyle changes and certain medications can help manage symptoms.

Most women undergoing chemotherapy experience hair loss, and many cope by using wigs or bonnets.

Improved care and timely diagnosis are needed for women with PCOD and PCOS, and CystaCare can help.

Chemotherapy may cause recurring hair loss due to an autoimmune response.

Early baldness increases prostate cancer risk, radiotherapy and surgery have similar second cancer rates, and ALA may reduce prostate cancer risk.

Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.

Hormonal dysfunctions, like PCOS, are common among reproductive-age women in India.

Imaging helps detect adrenal gland issues and monitor treatment in congenital adrenal hyperplasia, and can identify tumors affecting fertility.

Activating certain cells in hair follicles can prevent hair loss caused by cancer treatments.

Polycystic Ovarian Syndrome (PCOS) is a common condition causing fertility issues and other symptoms, with unclear causes and treatments focused on improving insulin sensitivity.

Obesity may weaken the immune system and increase cancer risk.

ICI therapy increases the risk of gastrointestinal and endocrine issues in psoriasis patients.

Long-term use of 5α-reductase inhibitors may improve survival in men with kidney cancer.

Finasteride use may be linked to rare testicular tumor, but more research needed.

Cyclosporine combined with other treatments can help hair regrow in severe alopecia areata, but it may cause side effects.

Prenatal and postnatal environments both affect PCOS development and gut microbiota in mice.

Targeting ACE2 and TMPRSS2 may help prevent or treat COVID-19 in cancer patients.

CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.

Women with PCOS who had antiandrogenic treatment before pregnancy had fewer complications than those without treatment.

A man with both skin lesions and lung cancer improved quickly with chemotherapy, suggesting the skin condition might be a reaction to immune system injury.

Androgen suppression therapy (AST) doesn't significantly lower bladder cancer risk, but using finasteride, a type of AST, might decrease the risk. AST also lessens the chance of cancer coming back but doesn't really affect survival rates. More research is needed to understand AST's benefits for different bladder cancers.

Benign ovarian tumors can cause excess male hormones and related conditions in postmenopausal women.

Half of the patients treated with a specific drug for skin cancer experienced hair loss not related to the drug's dosage.

Cancer risk is linked to the balance of mutations and environmental factors, not just the number of mutations.

Surgery to lower high testosterone in postmenopausal women with certain ovarian tumors doesn't significantly affect their metabolism.

A man developed male breast cancer after four years of finasteride treatment for an enlarged prostate.